There was a five-fold increased risk of VTE associated with cancer alone and the thrombotic risk due to FVL mutation was superimposed, with a twelve-fold increased risk as compared to individuals without cancer and FVL mutation (adjusted OR, 12.1 [95% CI, 1.6–88.1]). Here, F5 is linked to cancer.